WuXi and QIAGEN Form Biomarker Partnership
publication date: Jan 11, 2010
WuXi AppTec and QIAGEN formed a partnership focused on molecular biomarker development. QIAGEN will contribute a portfolio of instruments, training, and consumables which WuXi AppTec will use in its Shanghai laboratory, expanding its service offerings to its clients. WuXi will also help QIAGEN to develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that QIAGEN will market. More details...
Stock Symbol: (NYSE: WX)